The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108
administered via intravenous infusion in combination with standard radiation and
chemotherapy.
NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is
hoped to increase the effectiveness of radiation therapy.